Low-molecular weight human interleukin-1β antagonist discovered

Researchers described the detection of a human interleukin-1β antagonist with low molecular weight that disrupts interactions with the interleukin-1 receptor type I receptor.

Innovative approach by Waymark enhances health outcomes for Medicaid patients

Waymark, a public benefit company dedicated to improving access and quality of care in Medicaid, today published a peer-reviewed study in the New England Journal

October 18, 2024

Digital DNA melting analysis can be a faster and more reliable tool for pathogen detection

A new analysis method can detect pathogens in blood samples faster and more accurately than blood cultures, which are the current state of the art

February 21, 2024

Risk Adjusted Net Present Value: What is the current valuation of Pfizer’s Idrebormilast

The revenue for Idrebormilast is expected to reach an annual total of $43 mn by 2040 globally based off GlobalData’s Revenue Model. The drug’s revenue

July 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.